Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00215644
Status:
COMPLETED
Last Update Posted:
2018-11-02
First Post:
2005-09-15
Brief Title:
Matuzumab Treatment With Epirubicin Cisplatin and Capecitabine ECX in Esophago-Gastric Cancer
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Organization Data
Organization:
Merck KGaA Darmstadt Germany
Class:
INDUSTRY
Study ID:
EMD 72000-032
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Merck KGaA Darmstadt Germany
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None